Health & Medicinearticle2026-10-24

COMPANION-002: A Randomized Phase 2/3 Trial of Tovecimig Plus Paclitaxel versus Paclitaxel Alone as a Second-line Therapy in Patients with Advanced Biliary Tract Cancer

Open access0 citations

Abstract

Purpose Patients with previously treated biliary tract cancer (BTC) have a short median overall survival (OS), and few treatment options. Tovecimig, a bispecific antibody to delta-like ligand-4 and vascular endothelial growth factor (VEGF)-A, was evaluated in combination with paclitaxel in COMPANION-002, a randomized phase 2/3 study in pretreated patients with advanced BTC. Methods Patients with advanced BTC with one prior systemic therapy were randomized to paclitaxel (80 mg/m 2 ; days 1, 8 and 15) with or without tovecimig (10 mg/kg; days 1 and 15). The primary endpoint was RECIST v1.1-defined objective response rate (ORR) as assessed by blinded independent central review (BICR). Secondary endpoints included progression-free survival (PFS) and OS. Crossover from the paclitaxel control arm to tovecimig plus paclitaxel was permitted following BICR-confirmed progression. Results 168 patients were randomized 2:1 to tovecimig+paclitaxel (n=111) or paclitaxel alone (n=57). Tovecimig+paclitaxel significantly improved BICR-assessed ORR (18.0% vs 5.3%; P =.0228) and PFS (4.7 vs 2.6 months; hazard ratio [HR], 0.44; P <.0001). Among 31 patients (54%) who crossed over, post-progression PFS (time from crossover to subsequent second progression) exceeded initial PFS (PFS from randomization to initial progression on paclitaxel; 3.5 vs 1.9 months; HR, 0.40; P =.0035). Overall, 142 patients (85%) received tovecimig; no difference in OS was observed (HR, 1.05; P =.779). The most common treatment-emergent adverse events (TEAEs) with tovecimig+paclitaxel were hypertension (69.4%) and fatigue (66.7%). Grade ≥3 TEAEs occurred in 93.5% and 64.2% of patients treated with tovecimig+paclitaxel and paclitaxel alone, respectively. Conclusion Tovecimig combined with paclitaxel significantly improved ORR and PFS versus paclitaxel alone as second-line therapy for patients with BTC.

// Source

View paper (DOI)Open access versionOpenAlexJournal of Clinical OncologyPublished 2026-10-24

Authors: Nilofer Saba Azad, Zishuo I. Hu, Priyadarshini Pathak, İlyas Şahin, Olivia Aranha, Renuka V. Iyer, Gregory M. Heestand, Chih‐Yi Liao, Howard S. Höchster, Aparna Kalyan, Anthony B. El-Khoueiry, Andrew Scott Paulson, Robin Kate Kelley, Mitesh J. Borad, Lipika Goyal, Cynthia A. Sirard, Thomas J. Schuetz, Milind M. Javle

Institutions: Northwestern University, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, University of California, San Francisco, Washington University in St. Louis, The University of Texas MD Anderson Cancer Center, Stanford University, Sidney Kimmel Comprehensive Cancer Center, Stanford Medicine, Mayo Clinic in Arizona, Massachusetts General Hospital, Roswell Park Comprehensive Cancer Center, University of Chicago Medical Center, Stanford Health Care, USC Norris Comprehensive Cancer Center, University of Florida Health, UCSF Helen Diller Family Comprehensive Cancer Center, Rutgers Cancer Institute, Compass Therapeutics, Inc. (United States)